Longeveron Inc. CEO Wa'el Hashad will present at Biotech Showcase on January 14, 2025, discussing regenerative medicine developments.
Quiver AI Summary
Longeveron Inc., a clinical stage biotechnology company focused on regenerative medicine, announced that CEO Wa'el Hashad will present at the Biotech Showcase on January 14, 2025. The presentation will highlight the company's efforts in developing cellular therapies for serious and chronic aging-related conditions, specifically discussing their lead product, Lomecel-B, which is derived from young, healthy adult donors' bone marrow. Lomecel-B has potential applications in multiple areas, including hypoplastic left heart syndrome, Alzheimer's disease, and aging-related frailty, and has received several FDA designations. The presentation will be accessible via webcast on the company's website, with a replay available afterward.
Potential Positives
- Wa'el Hashad, the CEO, is scheduled to present at Biotech Showcase, indicating active engagement with the biotech community and potential investor interest.
- The company's lead investigational product, Lomecel-B, has received multiple important FDA designations, showcasing regulatory recognition and support for its development in critical areas.
- Longeveron's focus on addressing unmet medical needs in significant conditions such as Alzheimer's disease and hypoplastic left heart syndrome positions it favorably in the biotechnology market.
Potential Negatives
- Announcement of a presentation at an upcoming conference may imply the company is actively seeking investor interest, highlighting its need for additional capital or support at this clinical stage.
- The focus on multiple indications and the extensive FDA designations may also suggest a lack of definitive results or approvals thus far, raising concerns about the viability and progress of its lead therapy, Lomecel-B.
- Being classified as a clinical-stage biotechnology company emphasizes the high risks associated with its development pipeline, as tangible revenue-generating products are not yet available.
FAQ
What is Longeveron Inc. known for?
Longeveron Inc. is a clinical stage biotechnology company developing cellular therapies for chronic and life-threatening aging-related conditions.
When will Longeveron present at the Biotech Showcase?
Longeveron will present on January 14, 2025, from 4:00 to 4:30 p.m. PT.
How can I access the Longeveron presentation webcast?
The webcast can be accessed in the "Events and Presentations" section of the Company's website.
What is Lomecel-B?
Lomecel-B is an investigational MSC therapy product developed by Longeveron, targeting a range of chronic conditions.
What FDA designations has Longeveron received?
Longeveron has received Orphan Drug, Fast Track, Rare Pediatric Disease, and RMAT designations for its programs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LGVN Insider Trading Activity
$LGVN insiders have traded $LGVN stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here's a breakdown of recent trading of $LGVN stock by insiders over the last 6 months:
- KHOSO BALUCH sold 1,250 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LGVN Hedge Fund Activity
We have seen 11 institutional investors add shares of $LGVN stock to their portfolio, and 10 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RENAISSANCE TECHNOLOGIES LLC removed 146,700 shares (-100.0%) from their portfolio in Q3 2024
- GEODE CAPITAL MANAGEMENT, LLC added 97,953 shares (+316.0%) to their portfolio in Q3 2024
- TWO SIGMA INVESTMENTS, LP removed 46,041 shares (-100.0%) from their portfolio in Q3 2024
- VANGUARD GROUP INC added 44,984 shares (+inf%) to their portfolio in Q3 2024
- CITADEL ADVISORS LLC removed 22,485 shares (-100.0%) from their portfolio in Q3 2024
- SQUAREPOINT OPS LLC removed 17,831 shares (-100.0%) from their portfolio in Q3 2024
- STATE STREET CORP added 15,180 shares (+inf%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
MIAMI, Dec. 18, 2024 (GLOBE NEWSWIRE) --
Longeveron Inc.
(NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Wa'el Hashad, Chief Executive Officer, will give a corporate presentation at Biotech Showcase, being held January 13-15, 2025.
Details for the Company's presentation:
Date: | Tuesday, January 14, 2025 |
Time: | 4:00 – 4:30 p.m. PT |
The webcast for this conference presentation may be accessed at the "
Events and Presentations
" section of the Company's website. A replay of the webcast will be available on the Longeveron website following the conference.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company's lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease (AD), and Aging-related Frailty. Lomecel-B development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit
or follow Longeveron on
LinkedIn
,
X
, and
Instagram
.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
